Immune checkpoint inhibitors (ICIs), such as pembrolizumab and nivolumab, have shown remarkable efficacy in tumors exhibiting high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) due to their high mutational burden that enhances tumor immunogenicity.3,4 By inhibiting checkpoints such as PD-1/PD-L1 or CTLA-4, ICIs bolster T-cell-mediated immune responses against cancer cells. Here, CD274 is linked to neoplasm.